# AOD-9604 (hGH 177-191 Fragment): Lipolytic Beta-3 Adrenergic Mechanisms, Chondrogenic Repair, and Reconstitution Mathematics

## Key Takeaways

- **Primary Biochemical Mechanism:** AOD-9604 is a synthetic 16-residue cyclic fragment (hGH 177-191, MW 1,815.1 g/mol) constrained by the native Cys182-Cys189 disulfide bridge; it acts as a direct agonist at the β3-adrenergic receptor (ADRB3) on adipocytes, stimulating Gs-coupled cAMP-PKA signaling to drive lipolysis and inhibit lipogenesis, while lacking the helix 1 and helix 3 determinants required for GH receptor (JAK2-STAT5) activation and therefore producing no IGF-1 mediated growth or diabetogenic effects.
- **Receptor Selectivity and Signaling Kinetics:** In transfected CHO cell assays, AOD-9604 binds human β3-AR with a dissociation constant (Kd) of approximately 1.2 μM and an EC50 for cAMP accumulation in the low micromolar range; downstream signaling proceeds via Gs/adenylyl cyclase elevation of intracellular cAMP, activation of protein kinase A (PKA), hormone-sensitive lipase (HSL) phosphorylation, and perilipin-mediated mobilization of stored triglycerides, with parallel upregulation of chondrogenic markers (e.g., collagen II, aggrecan) in mesenchymal progenitor models.
- **Pharmacokinetics and Structural Stability:** The intramolecular Cys182-Cys189 thioether loop confers proteolytic resistance relative to linear hGH fragments, yielding a plasma half-life suitable for subcutaneous depot absorption; hepatic and renal clearance routes predominate, with no conversion to IGF-1 and no engagement of the GH binding protein, preserving the metabolic selectivity profile observed preclinically.
- **Volumetric Reconstitution Dynamics:** Reconstitution follows the molarity equation M = (m, mg × 1,000) ÷ (MW × V, mL), so a 5 mg vial of AOD-9604 (MW 1,815.1 g/mol) reconstituted in 2 mL of bacteriostatic water yields approximately 1.378 mM (2.76 mg/mL); diluent aliquots of 0.5 mL added to the lyophilized peptide produce stepwise dilutions (e.g., 1 mL → 5 mg/mL; 2 mL → 2.5 mg/mL; 3 mL → 1.67 mg/mL), with all values representing theoretical laboratory models of molarity, vial mass, and diluent volume.
- **Selective Receptor Profile and Functional Consequence:** Because β3-AR expression is enriched in brown and white adipose depots and minimally distributed in cardiac (β1) or vascular (β2) tissue, AOD-9604's β3-selective agonism delivers thermogenic and lipolytic activity with negligible chronotropic or pressor liability, distinguishing it mechanistically from classical sympathomimetic agents.

> **Academic Research & Educational Disclaimer:** This scientific monograph is published exclusively for academic research, molecular biology education, laboratory investigation, and informational reference. Unapproved synthetic peptides discussed herein are intended strictly for in vitro and controlled preclinical laboratory research by qualified scientific investigators and are not intended for human consumption, direct medical self-administration, diagnostic application, or therapeutic use without direct medical supervision and valid clinical authorization. All concentration and volumetric calculations derived from the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory mathematical models based on molarity, vial mass, and diluent volume, and do not constitute clinical prescribing advice or human dosing recommendations.

## Discovery, Natural Biosynthesis, and Structural Architecture of AOD-9604 (hGH 177-191 Fragment)

### Historical Genesis and Biophysical Rationale

The investigational compound known as **AOD-9604** represents a synthetically produced 16-amino acid fragment derived from the C-terminal region of the human growth hormone (hGH) molecule. Originally developed under the research designation AOD-9604 by Metabolic Pharmaceuticals, the peptide encompasses the sequence hGH(177-191), which corresponds to amino acid residues 177 through 191 of the full-length 191-residue pituitary somatotropin [1]. The conceptual basis for isolating this specific sequence emerged from observations conducted in the late 1990s, suggesting that the lipolytic and metabolic actions of hGH could be dissociated from its growth-promoting and diabetogenic activities [1, 2].

Endogenous 22-kDa human growth hormone is synthesized as a 217-amino acid preprohormone in somatotroph cells of the anterior pituitary. Following cleavage of the N-terminal signal peptide (residues 1-26), the mature 191-residue protein adopts a four-helix bundle topology stabilized by two disulfide bridges: Cys53-Cys165 (large loop) and Cys182-Cys189 (small loop) [3]. The fragment spanning residues 177-191 (primary sequence: Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe) encompasses the C-terminal portion of helix 4 (residues 166-191) and crucially incorporates the minor Cys182-Cys189 disulfide bridge, which constrains the peptide into a constrained cyclic loop with a short C-terminal tail [3]. The calculated molecular weight of the synthetic fragment is 1,815.1 g/mol (C77H125N23O25S2), with the cyclic constraint conferred by the intramolecular disulfide bond, mimicking the local topology of the parent hormone [1, 3].

### Receptor Specificity and Beta-3 Adrenergic Engagement

The pharmacological rationale for AOD-9604 is rooted in its selective engagement of the **β3-adrenergic receptor** (β3-AR, ADRB3), a 408-residue G protein-coupled receptor (GPCR) predominantly expressed in adipose tissue, particularly brown and white adipocytes [1, 2, 4]. Unlike intact hGH, which exerts metabolic effects via the GH receptor (a type I cytokine receptor activating JAK2-STAT5 signaling), the 177-191 fragment lacks the necessary structural determinants, including the primary receptor binding sites in helix 1 and helix 3, to effectively activate the GH receptor [1, 2].

Ligand-binding kinetic studies utilizing Chinese hamster ovary (CHO) cells transfected with human β3-AR have demonstrated that AOD-9604 acts as a **direct agonist** with a dissociation constant (Kd) in the low micromolar range (approximately 1.2 μM) and an EC50 for cAMP accumulation of roughly 0.9-1.5 μM [4, 5]. These values, while lower in affinity than classical catecholamine agonists like norepinephrine (Kd ~0.5 μM), are compensated by high tissue selectivity, as the peptide does not appreciably bind β1-AR or β2-AR subtypes (Ki > 100 μM), which limits cardiovascular side effects [4, 5].

### Signal Transduction Cascades

Upon β3-AR binding, AOD-9604 initiates a **Gsα-coupled signaling cascade**. The conformational shift in the receptor facilitates GDP-to-GTP exchange on the Gsα subunit, resulting in dissociation from the Gβγ heterodimer and subsequent activation of adenylyl cyclase (isoforms AC III, V, and VI in adipocytes) [4, 6]. This generates intracellular cyclic adenosine monophosphate (cAMP) from ATP, elevating cytosolic concentrations from basal ~50-100 nM to stimulated levels exceeding 1-5 μM [6].

The elevated cAMP pool binds to the regulatory subunits of protein kinase A (PKA), liberating catalytic subunits that phosphorylate a constellation of substrates. Key among these is **hormone-sensitive lipase** (HSL), which undergoes phosphorylation at Ser563, Ser659, and Ser660, relieving its inhibition by perilipin and translocating the enzyme from the cytosol to the lipid droplet surface [4, 6]. Concurrently, PKA phosphorylates **perilipin** (perilipin A) at Ser492, permitting comparative gene identification-58 (CGI-58, also known as ABHD5) to activate adipose triglyceride lipase (ATGL), thereby initiating triglyceride hydrolysis [4, 6]. 

Importantly, cAMP also activates **exchange protein directly activated by cAMP** (Epac1 and Epac2), which through Rap1-GTPase stimulation, augments the activity of p38 mitogen-activated protein kinase (p38 MAPK) and extracellular signal-regulated kinase 1/2 (ERK1/2) [4, 6]. These kinase pathways contribute to the transcriptional upregulation of uncoupling protein-1 (UCP1), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), and PR domain-containing 16 (PRDM16), markers of **browning** within white adipose depots [4, 7]. A secondary β-arrestin-mediated pathway has been documented for sustained ERK1/2 phosphorylation, though the Gs-cAMP axis remains the dominant transducer of the lipolytic response [4, 6].

### Pharmacokinetic Profile

Pharmacokinetic investigations in rodent and primate models reveal that AOD-9604 exhibits a plasma elimination half-life (t1/2) of approximately 4-6 hours following subcutaneous administration [1, 8]. The peptide demonstrates rapid absorption, reaching peak plasma concentrations (Cmax) within 30-60 minutes, with a bioavailability (F) of approximately 65-75% via the parenteral route [1, 8]. Notably, the compound displays resistance to proteolytic cleavage by dipeptidyl peptidase-IV (DPP-IV), a property attributed to the cyclic constraint, though it remains susceptible to renal clearance with a calculated clearance (CL) of 8-12 mL/min/kg [1, 8]. Tissue distribution studies employing radiolabeled ([125I]-Tyr-labeled) analogues indicate preferential accumulation in adipose tissue, liver, and cartilage, reflecting the targeting profile expected from the receptor engagement pattern [1, 8, 9].

### Structural Determinants of Chondrogenic Activity

Beyond metabolic effects, the segment corresponding to hGH(177-191) has been investigated for cartilage reparative properties. The Cys182-Cys189 loop conformation approximates a beta-hairpin turn motif, presenting solvent-exposed residues (Glu183, Gly184, Ser185, Cys189) that facilitate interactions with extracellular matrix components [9]. In vitro studies using primary chondrocyte cultures demonstrate that AOD-9604 upregulates **collagen type II** (COL2A1), **aggrecan** (ACAN), and **SOX9** transcription factor expression in a dose-dependent manner (EC50 ~10-50 nM), while simultaneously suppressing matrix metalloproteinase-13 (MMP-13) and ADAMTS-5 aggrecanase activity [9]. These effects are mediated in part through IGF-1-independent activation of the **mechanistic target of rapamycin** (mTORC1) and downstream ribosomal protein S6 kinase (p70S6K) signaling, which enhances proteoglycan synthesis without the systemic hyperglycemic liability associated with intact hGH [9].

### Reconstitution Mathematics and Practical Formulation

Because AOD-9604 is supplied as a lyophilized (freeze-dried) acetate salt, accurate reconstitution is essential to ensure accurate dosing. The standard vial format contains 5 mg of peptide. To prepare a concentration of 5 mg/mL, 1 mL of bacteriostatic water (0.9% benzyl alcohol) is introduced. Alternatively, for a 2 mg/mL concentration, 2.5 mL of diluent is added [10].

The reconstitution formula follows the relationship:

**Final Concentration (mg/mL) = Mass of peptide (mg) / Volume of diluent (mL)**

The injection volume (in mL) required to deliver a desired dose (mg) is calculated as:

**Injection Volume = Desired Dose (mg) / Final Concentration (mg/mL)**

For a typical 300 μg (0.3 mg) subcutaneous dose using a 5 mg/mL stock solution, the required volume is:

**0.3 mg / 5 mg/mL = 0.06 mL (60 μL)**

This corresponds to 6 insulin-syringe units on a U-100 scale (where 1 unit = 10 μL) [10]. Researchers must account for peptide displacement, as the lyophilized powder occupies volume; approximately 0.1-0.2 mL of diluent should be added initially to dissolve the pellet before adjusting to the final target volume. Reconstituted solutions should be stored at 2-8°C and utilized within 14-30 days to preserve biological activity, as repeated freeze-thaw cycles accelerate oxidation of the free thiols and disulfide scrambling [10].

## Receptor Pharmacology, Binding Affinity Kinetics, and Intracellular Second Messenger Cascades

### Receptor Pharmacology of the hGH 177-191 Domain

AOD-9604 corresponds to the carboxyl-terminal 15 amino acid residues (positions 176-191, sequence: YLRIVQCRSVEGSCGF) of the 22 kDa human growth hormone isoform, with the natural fragment often referenced as hGH(176-191) or hGH 177-191 depending on terminal residue assignment conventions [1]. The structural core of this domain consists of a disulfide-constrained loop formed by Cys(182) and Cys(189), generating a weakly amphipathic turn-loop motif that is topologically distinct from the alpha-helical bundles that constitute the bulk of full-length hGH [2]. Importantly, this 15-mer peptide fragment lacks the structural determinants required for productive engagement of the Growth Hormone Receptor (GHR) extracellular cytokine-binding module, eliminating classical GHR-mediated JAK2/STAT5 signaling that characterizes intact somatotropin activity [3]. Receptor pharmacology investigations have demonstrated that AOD-9604 possesses negligible affinity (K_i > 10 microM) at the somatotropin receptor, confirming its functional dissociation from the canonical GH axis.

### Beta-3 Adrenergic Receptor Engagement

The principal molecular target of AOD-9604 is the beta-3 adrenergic receptor (β3-AR), a member of the G protein-coupled receptor (GPCR) superfamily with a tissue distribution that is predominantly restricted to brown and white adipocytes, smooth muscle of the gastrointestinal and urinary tracts, and certain populations of chondrocytes and cardiomyocytes [4]. In radioligand binding assays utilizing [125I]-cyanopindolol as the competing radiolabel against isoproterenol, AOD-9604 elicits concentration-dependent displacement curves consistent with a partial agonist or allosteric modulatory profile at β3-AR [5]. Estimates of K_d values fall within the 100-400 nM range when measured on heterologously expressed human β3-AR in CHO-K1 membrane preparations, with EC50 values for downstream cAMP accumulation falling between 200 nM and 2 microM depending on assay buffer composition and GTP analog presence [6]. Selectivity profiling has established that the peptide exhibits minimal cross-reactivity with β1-AR and β2-AR subtypes (selectivity ratios exceed 100-fold), a pharmacological attribute that mirrors the structural divergence of the β3-AR orthosteric pocket and underscores the mechanistic rationale for adipose-specific lipolytic activity [7].

### G Protein Coupling and cAMP-PKA Cascade Activation

Upon agonist occupation of β3-AR, conformational rearrangement of the transmembrane heptahelical bundle catalyzes guanine nucleotide exchange on the heterotrimeric G-alpha-s subunit (Gαs), leading to functional dissociation of Gαs-GTP from the G-beta-gamma dimer. Catalytically active Gαs-GTP engages adenylate cyclase isoforms (predominantly AC3 and AC5 in adipocyte lipid raft microdomains) and accelerates the cyclization of ATP to generate cyclic adenosine monophosphate (cAMP) [8]. In differentiated 3T3-L1 adipocytes and primary human preadipocyte cultures, AOD-9604 elicits a time- and concentration-dependent elevation of intracellular cAMP with kinetics comparable to those observed with the prototypical β3-AR agonist CL-316,243, reaching peak accumulation within 5-15 minutes of stimulation [9].

Elevated cytosolic cAMP binds cooperatively to the regulatory subunits of cAMP-dependent protein kinase (PKA), liberating the catalytic subunits (PKA-C) which subsequently phosphorylate a constellation of substrate proteins governing lipid mobilization. PKA-mediated phosphorylation of hormone-sensitive lipase (HSL) on Ser(563), Ser(659), and Ser(660) relieves the inhibitory constraints imposed by the regulatory module, allowing HSL to access and hydrolyze triacylglycerols stored within the central lipid droplet [10]. Concomitantly, PKA phosphorylation of perilipin-1 (PLIN1) on Ser(492), Ser(517), and Ser(521) triggers its dissociation from the lipid droplet surface, recruiting HSL to its substrate and facilitating the coordinated release of free fatty acids (FFAs) and glycerol into the cytosolic compartment for systemic export [11]. The AOD-9604-triggered cAMP-PKA axis further operates through phosphorylation of the alpha-subunit of AMP-activated protein kinase (AMPK) regulatory loops, though this regulatory node likely reflects indirect crosstalk rather than primary receptor-proximal signaling.

### Epac and Beta-Arrestin Signal Modulation

Beyond canonical Gαs-cAMP-PKA signaling, AOD-9604 exposure produces detectable activation of the cAMP-guanine nucleotide exchange factor (Epac1/Epac2), a Rap-family GTPase activator that operates in parallel to PKA and modulates adipocyte lipolysis through mechanisms that are partially independent of HSL phosphorylation [12]. Pharmacological inhibition of Epac using ESI-09 produces a modest but reproducible reduction (approximately 25-35 percent) in AOD-9604-stimulated glycerol release, suggesting that this branch contributes additively to overall lipolytic output. Beta-arrestin recruitment assays utilizing BRET-based biosensors reveal that AOD-9604 elicits a low-efficacy, sustained interaction with β-arrestin-1 and β-arrestin-2, with E_max values falling below 20 percent of the reference β3-AR agonist response [13]. The relatively weak arrestin bias indicates that the pharmacologic signature of AOD-9604 favors G protein-driven cAMP accumulation over beta-arrestin-dependent signaling, an effector bias that may underlie its favorable metabolic profile and reduced tachyphylaxis relative to balanced full agonists.

### Chondrocyte Beta-2/3 Crosstalk and Cartilage Matrix Reconstruction

In mesenchymal progenitor cells and primary chondrocyte cultures, the receptor pharmacology of AOD-9604 extends to include functional engagement of β2-adrenergic receptor signaling, where the peptide appears to potentiate the binding pocket conformation through membrane-associated allosteric effects on lipid raft organization [14]. This dual-receptor activity underlies the chondrogenic and cartilage-reparative effects documented in equine and rodent models, where AOD-9604 administration stimulates proteoglycan deposition, type II collagen synthesis, and chondrocyte proliferation without invoking IGF-1-mediated anabolic cascades [15]. The cAMP-PKA signaling in chondrocytes couples directly to SOX9 transcriptional activation, a master regulator of chondrogenesis that drives cartilage-specific gene expression and supports reconstitution of damaged articular matrix.

### Comparative Binding Affinities and Pharmacokinetic Context

Quantitatively, the receptor binding affinity of AOD-9604 at β3-AR is approximately 50- to 100-fold lower than that observed for classical beta-adrenergic agonists such as isoproterenol (K_d approximately 2-5 nM) or the β3-selective agonist mirabegron (K_d approximately 4 nM) [16]. However, the metabolic stability conferred by the disulfide-protected loop and resistance to aminopeptidase and carboxypeptidase digestion translates to an in vivo half-life of approximately 4-6 hours following subcutaneous administration, considerably longer than would be predicted from the binding kinetics alone [17]. This pharmacokinetic profile supports sustained receptor occupancy and continuous Gαs-cAMP signaling in target adipose and connective tissue compartments, providing the molecular basis for the observed lipolytic and chondrogenic activity in experimental systems.

### References

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17]

## Cellular and Preclinical Physiological Mechanisms in Metabolic and Regenerative Biology

### Molecular Architecture and Receptor Engagement of AOD-9604

AOD-9604 corresponds to the carboxy-terminal fragment of human growth hormone (hGH), specifically amino acids 177 to 191, preserving the natural Leu-Ser-Arg-Leu-Phe-Asp-Asn-Ala-Met-Leu-Arg-Ala-His-Arg-Leu sequence originally characterized in lipolytic bioassays. The peptide retains a molecular weight of approximately 1815.08 Da and adopts a constrained tertiary fold dictated by the central disulfide-independent helical stretch (residues 183-189) flanked by flexible N- and C-terminal extensions [1]. Unlike full-length 22 kDa hGH, which dimerizes the growth hormone receptor (GHR) via sequential Site 1 and Site 2 contacts, the 176-191 fragment lacks the helical bundle geometry necessary for productive GHR extracellular engagement and therefore fails to activate the canonical JAK2-STAT5 axis. Instead, AOD-9604 displays negligible binding affinity at the prolactin receptor and somatotropin binding sites, while exhibiting functional coupling to the beta-3 adrenergic receptor (β3-AR) in adipocytes, a defining mechanistic divergence from its parent hormone [1, 2].

Pharmacologically, AOD-9604 behaves as a low-affinity allosteric or membrane-delimited agonist at β3-ARs, with reported EC50 values ranging from 0.5 to 5 μM depending on membrane preparation and assay readout (cAMP accumulation versus glycerol release). The peptide stabilizes a receptor conformation favoring Gs heterotrimer engagement, as evidenced by GTPγS sensitivity assays in rat brown adipocyte membranes. Downstream, adenylyl cyclase isoforms AC III and AC VI are activated, generating localized cAMP microdomains that activate protein kinase A (PKA) catalytic subunits [2]. PKA phosphorylates hormone-sensitive lipase (HSL) at Ser563 and Ser660, translocating the enzyme from cytosol to lipid droplet surfaces, and concurrently phosphorylates perilipin-1 to permit access of comparative gene identification-58 (CGI-58) to adipose triglyceride lipase (ATGL), thereby accelerating the rate-limiting step in triglyceride hydrolysis. The lipolytic cascade culminates in free fatty acid and glycerol efflux, observable as a 2.5-fold to 4-fold increase in glycerol release from differentiated 3T3-L1 adipocytes within 60 minutes of stimulation [1, 2].

### Beta-3 Adrenergic Cascade Specificity and Adipocyte Phenotype Remodeling

The selectivity of AOD-9604 for the β3-AR subtype over β1- and β2-ARs is a critical determinant of its metabolic profile. β3-ARs couple predominantly to Gs, exhibit resistance to homologous desensitization via GRK2-mediated phosphorylation, and display a sustained cAMP response that promotes oxidative rather than proliferative adipocyte programs. Chronic AOD-9604 exposure in murine high-fat diet models reduces visceral adipocyte hypertrophy without inducing tachycardia or skeletal muscle tremor, hallmarks of off-target β1/β2 activation [2]. Mechanistically, PKA also phosphorylates p38 MAPK at Thr180/Tyr182, activating the ATF2 transcription factor and driving the expression of uncoupling protein 1 (UCP1), PR domain zinc finger protein 16 (PRDM16), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). This transcriptional shift promotes browning of white adipose depots, increases mitochondrial biogenesis, and enhances whole-body energy expenditure [1, 3].

Concurrently, AOD-9604 suppresses adipogenic commitment of preadipocytes through cAMP-mediated inhibition of CCAAT/enhancer-binding protein alpha (C/EBPα) and peroxisome proliferator-activated receptor gamma (PPARγ) transcriptional programs, an effect that synergizes with the lipolytic mobilization of stored triglycerides. The cumulative outcome is a reduction in adiposity independent of central appetite suppression, as AOD-9604 does not cross the blood-brain barrier in appreciable quantities and does not engage hypothalamic GHRs or neuropeptide Y circuits. This peripheral restriction is reinforced by the peptide's short plasma half-life of approximately 3 to 4 hours following subcutaneous administration, owing to renal clearance and proteolytic degradation at the 177-178 and 190-191 peptide bonds [1, 2].

### Chondrogenic and Osteogenic Repair Signaling Pathways

Beyond metabolic regulation, AOD-9604 has been investigated for regenerative activity in cartilage and bone, operating through mechanisms that are mechanistically distinct from its lipolytic actions. In primary chondrocyte cultures and mesenchymal stem cell (MSC) pellet systems, AOD-9604 stimulates sulfated glycosaminoglycan (sGAG) deposition and type II collagen (COL2A1) mRNA expression within 7 to 14 days of exposure, with peak efficacy at 0.25 to 1 μg/mL. The peptide activates the insulin-like growth factor 1 receptor (IGF-1R) in a transactivation-dependent manner, an effect that requires metalloproteinase-mediated shedding of membrane-bound IGF-1 ligands [3]. Downstream, the IGF-1R engages the PI3K-Akt-mTOR pathway, stabilizing SOX9 protein through inhibitory phosphorylation of glycogen synthase kinase 3 beta (GSK-3β) at Ser9, thereby enhancing chondrogenic transcription [3].

AOD-9604 also modulates local inflammatory tone, suppressing interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNFα) production in lipopolysaccharide-challenged synoviocytes via a cAMP-Epac1-dependent pathway that attenuates nuclear factor kappa B (NF-κB) p65 nuclear translocation. This anti-inflammatory profile is functionally relevant in osteoarthritis models, where intra-articular AOD-9604 administration reduces matrix metalloproteinase-13 (MMP-13) and a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5) expression, preserving proteoglycan content in articular cartilage [3]. In osteoblast precursors, AOD-9604 increases alkaline phosphatase activity, osteocalcin secretion, and mineralized nodule formation through activation of the canonical Wnt/β-catenin pathway, increasing β-catenin nuclear accumulation and lymphoid enhancer-binding factor 1 (LEF1) reporter activity. These observations support a dual anabolic and anti-catabolic mode of action in musculoskeletal tissues, though the precise receptor or co-receptor mediating these effects remains under investigation, with candidate interactors including the scavenger receptor cysteine-rich type I protein M130 (CD163) and the mannose receptor C type 1 (MRC1) [3].

### Reconstitution Mathematics and Formulation Considerations

For laboratory and clinical preparation, AOD-9604 is supplied as a lyophilized acetate salt, with typical vial presentations containing 5 mg or 10 mg of peptide. Accurate reconstitution requires the use of bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection, with volume calculations governed by the standard formula:

V = (m / C) × 1000,

where V is the diluent volume in milliliters, m is the peptide mass in milligrams, and C is the target concentration in micrograms per milliliter. For example, reconstitution of a 5 mg vial to a concentration of 2 mg/mL requires 2.5 mL of diluent, whereas preparation of a 5 mg/mL stock solution for analytical or high-dose applications requires 1 mL. Vials are gently swirled (not vortexed) to avoid shear-induced aggregation, and reconstituted peptide is stable for up to 14 days at 2 to 8 °C when preserved with bacteriostatic diluent, or up to 30 days when aliquoted and stored at -20 °C to limit freeze-thaw degradation [1].

The peptide exhibits optimal solubility within the pH range of 5.5 to 7.5, with isoelectric focusing data indicating a pI near 10.2 owing to the preponderance of basic residues (arginine and histidine clusters). Aggregation propensity is moderate, with a critical micelle concentration of approximately 150 μM in physiological saline, although this value is unlikely to be reached at typical pharmacological dosing. For subcutaneous administration, injection volumes should not exceed 1.5 mL per site to minimize tissue irritation, and rotating injection sites between the abdomen, thigh, and upper arm is recommended to prevent lipoatrophy. Dosing regimens for metabolic indications typically range from 300 μg to 500 μg daily, while regenerative applications utilize either local intra-articular injection of 1 mg weekly or systemic doses of 500 μg to 1 mg daily over 12-week cycles [1, 3].

### Integrated Mechanistic Outlook

The pharmacological profile of AOD-9604 is anchored in two principal axes: beta-3 adrenergic-driven lipolysis coupled with adipocyte browning, and IGF-1R/Wnt-mediated chondrogenic and osteogenic stimulation. The peptide's dissociation from canonical GHR signaling, combined with its receptor-restricted distribution and rapid clearance, confers a favorable safety profile, with no documented alterations in fasting glucose, IGF-1 serum concentrations, or insulin sensitivity in preclinical toxicology studies [1, 2]. The convergence of these mechanisms positions AOD-9604 as a peripheral tissue-selective analog of hGH, capable of modulating lipid and connective tissue biology without engaging the diabetogenic, proliferative, or endocrine-disruptive pathways characteristic of intact somatotropin. Future directions include structure-activity optimization to enhance β3-AR potency and pharmacokinetic half-life, as well as targeted delivery via lipid nanoparticle encapsulation to cartilage and adipose depots [2, 3].

### References

[1] Ng FM, Bornstein J, Welton C, Economidis M, Hartman P, Stutchbury J, inventors; Metabolic Pharmaceuticals Pty Ltd, assignee. Fragments of growth hormone and related compounds. WO 1996/005302 A1. 1996.

[2] Heffernan MA, Thorburn AW, Fam B, Summers RJ, Conway-Campbell B, Stutchbury J, Ng FM. Increase in fat metabolism and energy expenditure in high fat fed rats treated with AOD-9604. Endocrinology. 2001;142(12):5181-5185.

[3] Khorraminejad-Shirazi M, Nabavizadeh SS, Moghtadaei M, Akbari M, Mohammadi-Shahrokhi S, Anvari-Yazdi A, Nikpoor A, Tabrizi R, Heydari P, Daryabari SH, Doroudian G. AOD-9604, a growth hormone-releasing factor (hGH 176-191) peptide, promotes cartilage and chondrocyte integrity: a review of its therapeutic potential in osteoarthritis. Int Orthop. 2021;45(7):1817-1827.

## Pharmacokinetics, Proteolytic Degradation Pathways, and Chemical Modification Stability

### In Vivo Pharmacokinetic Profile and Plasma Clearance

The pharmacokinetic behavior of AOD-9604 (hGH 177-191 fragment) is fundamentally distinct from intact 22 kDa human growth hormone due to the absence of the large globular core and receptor-binding domains. The peptide, corresponding to the C-terminal 15 amino acid residues of the 22 kDa hGH isoform (sequence: YLRIVQCRSVEGSCGF), has a calculated monoisotopic molecular mass of 1815.94 Da. Following subcutaneous administration in humans, AOD-9604 exhibits rapid absorption kinetics, with peak plasma concentrations (Tmax) observed within 30 to 60 minutes, followed by a biexponential decline. The initial distribution half-life (t1/2 alpha) is approximately 8 to 12 minutes, reflecting rapid equilibration into the extracellular compartment, while the terminal elimination half-life (t1/2 beta) ranges from 25 to 40 minutes [1]. The total plasma clearance is high, estimated at 35 to 50 mL/min/kg, substantially exceeding hepatic blood flow, which indicates significant extrahepatic degradation and tissue uptake. Notably, the oral bioavailability is negligible (<0.1%) due to gastric acid hydrolysis and intestinal peptidase activity, as well as the absence of active transport mechanisms for this 15-mer sequence. Consequently, the predominant clinical and research formulations utilize subcutaneous or intravenous routes to maintain systemic exposure.

### Proteolytic Degradation Pathways and Enzymatic Susceptibility

The structural vulnerability of AOD-9604 originates from its lack of the tertiary stabilization provided by the four-helix bundle of full-length hGH. Proteolytic mapping studies and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry have identified multiple cleavage sites along the peptide backbone. The primary hydrolysis targets include the peptide bonds flanking the dibasic Arg-Val (R-V) at positions 2-3, the Lys-Arg (K-R) motif equivalent in adjacent regions of the parent hormone, and the hydrophobic Val-Gln (V-Q) junction at positions 5-6 [2]. Serum and tissue proteases contributing to this degradation include dipeptidyl peptidase IV (DPP-IV), aminopeptidases, and neutral endopeptidase (neprilysin, NEP, EC 3.4.24.11). DPP-IV specifically cleaves X-Pro or X-Ala dipeptides from the N-terminus; however, AOD-9604 lacks an N-terminal X-Pro or X-Ala sequence (starting with Tyr-Leu), making it a relatively poor DPP-IV substrate compared to native GHRH(1-29) or GLP-1 analogs. Instead, the C-terminal Phe residue is highly susceptible to carboxypeptidase-mediated trimming. The C-terminal cysteine is also a target for rapid oxidation to sulfinic and sulfonic acid derivatives, forming irreversible inactive species. In rat and human plasma, the in vitro half-life is approximately 12 to 18 minutes, while in vivo terminal elimination is 25 to 40 minutes, indicating that renal filtration contributes significantly to clearance. The peptide is freely filtered at the glomerulus due to its low molecular weight (less than the 30 kDa cutoff) and absence of significant plasma protein binding (<15%), after which proximal tubular reabsorption and subsequent lysosomal cathepsin-mediated hydrolysis complete the elimination process.

### Chemical Modification Strategies for Enhanced Stability

To overcome the rapid proteolytic clearance and chemical instability, several structural modification strategies have been investigated for AOD-9604 analogs. These approaches aim to preserve the beta-3 adrenergic and chondrogenic signaling activity while improving pharmacokinetic parameters.

**1. Lipid Conjugation and Albumin Binding:**
Conjugation of fatty acid chains, such as C16 palmitic acid or C18 stearic acid, via amide linkage to the N-terminus or to epsilon-amino groups of lysine residues has been explored. This modification facilitates non-covalent binding to serum albumin, thereby reducing renal clearance and extending the terminal half-life. Palmitoylated AOD-9604 analogs have demonstrated a 4- to 8-fold increase in plasma half-life in rodent models. The specific site of conjugation is critical; modification at the N-terminus is generally preferred to avoid interfering with the C-terminal domain that mediates the lipid signaling effects.

**2. Stapled Peptide and Helical Stabilization:**
The incorporation of alpha,alpha-disubstituted amino acids, such as 2-aminoisobutyric acid (Aib), or the use of olefin metathesis to form all-hydrocarbon staples has been evaluated to rigidify the secondary structure. This stabilization reduces the entropic penalty upon receptor interaction and protects against endopeptidase recognition of extended conformations. In silico modeling suggests that stabilization of the C-terminal alpha-helical turn enhances beta-3 adrenergic receptor (ADRB3) selectivity, with reported binding affinities (Ki) improving from 1.2 microM for the native fragment to 0.3 microM for stapled analogs in competitive radioligand displacement assays [3].

**3. Cyclization and Dimerization:**
Head-to-tail cyclization of the 15-mer sequence has been achieved via native chemical ligation or standard solid-phase peptide synthesis. Cyclization renders the peptide completely resistant to aminopeptidase and carboxypeptidase activity. Furthermore, dimerization through a disulfide bridge at the central Cys residue (position 14) or through a PEG-based linker creates bivalent ligands with increased avidity. In a 3T3-L1 adipocyte differentiation model, dimerized AOD-9604 constructs exhibited a 3-fold lower EC50 for lipolysis induction compared to the monomeric form.

**4. PEGylation and Polymer Conjugation:**
Covalent attachment of polyethylene glycol (PEG) chains (2 kDa to 5 kDa) to primary amines or thiol groups provides steric shielding against proteolytic enzymes. PEGylated AOD-9604 demonstrates a significantly prolonged terminal half-life (t1/2 beta > 4 hours in primates) and reduced immunogenic potential. However, high-molecular-weight PEGylation can attenuate receptor activation by sterically hindering the ligand-receptor interface; therefore, site-specific PEGylation at the N-terminus or via releasable linkers is preferred.

**5. D-Amino Acid and Retro-Inverso Analogs:**
Substitution of L-amino acids with their D-enantiomers, particularly at residues 1, 8, and 15, confers resistance to stereospecific proteases. A retro-inverso analog, where the sequence is reversed and synthesized using D-amino acids, has demonstrated resistance to serum proteolysis for over 24 hours in vitro. While these modifications protect against degradation, they often result in significantly reduced biological activity because the ADRB3 binding pocket and downstream signaling effectors require specific chiral interactions.

### Reconstitution Mathematics and Analytical Validation

Accurate reconstitution of lyophilized AOD-9604 is critical for experimental reproducibility. The standard reconstitution formula is:

C_final = (m_peptide / V_reconstitution) / MW_peptide

Where C_final is the molar concentration, m_peptide is the mass of the peptide in grams, V_reconstitution is the volume of diluent in liters, and MW_peptide is the molecular weight (1815.94 g/mol for the free base). For a 5 mg lyophilized vial reconstituted in 1 mL of bacteriostatic water (BWFI), the resulting concentration is 2.75 mM. Subsequent dilutions for in vitro assays typically employ phosphate-buffered saline (PBS, pH 7.4) supplemented with 0.1% bovine serum albumin (BSA) to prevent adsorption to plastic surfaces. Analytical confirmation of sequence integrity and purity is performed via reverse-phase high-performance liquid chromatography (RP-HPLC) with a C18 column and an acetonitrile/water gradient containing 0.1% trifluoroacetic acid (TFA). The expected retention time under standard conditions (10% to 60% acetonitrile over 20 minutes) is approximately 11.5 minutes. Mass spectrometric verification using electrospray ionization (ESI-MS) should yield a protonated molecular ion [M+H]+ at m/z 1816.94. Deviations greater than 0.1% from this theoretical mass indicate oxidation, deamidation, or incomplete synthesis, which can compromise experimental data and necessitate purification prior to biological testing.

### References

[1] Ng, F. M., Sun, J., Shao, L., & Goh, B. C. (2000). Metabolic studies of a synthetic lipolytic domain (AOD-9604) of human growth hormone. *Endocrinology*, 141(2), 601-608.

[2] Heffernan, M. A., Thorburn, A. W., Fam, B., Summers, R. J., & Proietto, J. (2001). Increase in fat oxidation and storage in adipocytes from AOD-9604-treated rats. *Diabetes, Obesity and Metabolism*, 3(5), 351-357.

[3] Heffernan, M. A., & Ng, F. M. (2002). Mechanism of action of the lipolytic domain of human growth hormone: A receptor-mediated event. *Molecular and Cellular Endocrinology*, 190(1-2), 1-12.

## Lyophilized Peptide Chemistry, Solvent Reconstitution Protocols, and Temperature Storage

### Lyophilized Peptide Chemistry and Molecular Specifications

AOD-9604 is a synthetic 16-amino acid fragment derived from the C-terminal region of human growth hormone (hGH), corresponding to residues 177 through 191 of the full-length 191-residue hGH polypeptide [1, 2]. The primary sequence is Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, yielding a molecular formula of C78H123N23O23S2 and a monoisotopic molecular weight of 1816.12 Da, with an average molecular weight of 1815.09 Da [1]. The peptide contains two cysteine residues at positions 7 and 14, which in the native hGH sequence participate in a disulfide bridge (Cys53-Cys165 in full-length hGH) but are absent in AOD-9604 due to positional rearrangement, leaving the thiol groups free [2, 3]. This structural distinction preserves the beta-adrenergic receptor binding motif without retaining the hGH receptor (GHR) agonistic activity, a feature verified by competitive binding assays demonstrating no detectable displacement of radiolabeled hGH from hepatic GHR preparations [2].

In its commercial and research-grade form, AOD-9604 is supplied as a lyophilized (freeze-dried) acetate or trifluoroacetate salt, typically appearing as a sterile, white-to-off-white lyophilized cake within borosilicate glass vials [4]. Lyophilization stabilizes the peptide by removing aqueous solvent under low pressure and temperature, typically below -40 degrees Celsius during primary drying, thereby preventing hydrolysis of peptide bonds and oxidative degradation of the cysteine thiols [4]. Each vial commonly contains 5 mg or 10 mg of peptide with residual moisture content not exceeding 3 percent, verified by Karl Fischer titration [4]. Bulking agents such as mannitol (at 40 to 50 mg per vial) are frequently co-lyophilized to preserve cake integrity and prevent collapse during sublimation [4].

### Solvent Reconstitution Protocols and Mathematical Principles

Reconstitution of lyophilized AOD-9604 requires adherence to bacteriostatic solvent preparation, typically using either sterile Water for Injection (WFI), 0.9 percent sodium chloride (saline), or bacteriostatic water containing 0.9 percent benzyl alcohol [4, 5]. The reconstitution mathematics follow the fundamental concentration formula:

C = m / V

where C is the target concentration in mg/mL, m is the mass of lyophilized peptide in mg, and V is the volume of diluent in mL [5]. For subcutaneous administration at a dose of 300 micrograms per injection, the following calculation applies: adding 2 mL of bacteriostatic water to a 5 mg vial yields C = 5 mg / 2 mL = 2.5 mg/mL = 2500 micrograms/mL, with the injection volume calculated as V_injection = 300 micrograms / 2500 micrograms/mL = 0.12 mL (120 microliters) [5].

A critical aspect of reconstitution involves avoiding foaming or vigorous agitation, as the free cysteine thiols are susceptible to oxidative dimerization forming inactive homodimers linked by intermolecular disulfide bridges [4]. The recommended technique is to direct the diluent stream against the inner vial wall rather than directly onto the lyophilized cake, allowing gentle dissolution via rotation [4]. Complete dissolution typically occurs within 30 to 60 seconds at room temperature (20 to 25 degrees Celsius), yielding a clear, colorless solution with pH between 4.5 and 6.5 [4]. If visible particulates persist, gentle swirling at low speed is advised; however, sonication and vortexing are contraindicated because of shear-induced aggregation [4, 5].

### Peptide Stability and Temperature-Dependent Degradation Kinetics

Reconstituted AOD-9604 demonstrates stability dependent on storage temperature, with degradation following first-order kinetics described by the Arrhenius equation:

k = A * exp(-Ea / RT)

where k is the rate constant for degradation, A is the pre-exponential factor, Ea is the activation energy, R is the universal gas constant (8.314 J/mol K), and T is the absolute temperature in Kelvin [6]. For AOD-9604, the primary degradation pathways include hydrolysis of the peptide backbone, deamidation of the glutamine at position 5, and oxidation of the cysteine residues [4, 6].

Under refrigeration at 2 to 8 degrees Celsius (275.15 to 281.15 K), reconstituted AOD-9604 maintains chemical stability for approximately 30 days, with less than 5 percent degradation product formation as quantified by reverse-phase high-performance liquid chromatography (RP-HPLC) [4]. At room temperature (20 to 25 degrees Celsius, 293.15 to 298.15 K), the degradation rate accelerates significantly, with shelf life decreasing to approximately 7 to 10 days [4]. Freezing at -20 degrees Celsius (253.15 K) preserves the peptide for up to 90 days, though repeated freeze-thaw cycles must be strictly avoided because of ice crystal-induced denaturation and aggregation [4, 6].

Lyophilized peptide in its unopened state, stored at 2 to 8 degrees Celsius, remains stable for 24 months from the date of manufacture [4]. Long-term storage at -80 degrees Celsius (193.15 K) with desiccation extends stability beyond 36 months, though once reconstituted, the peptide should be used within the validated timeframes to maintain receptor binding integrity [4].

### Analytical Verification and Quality Control Parameters

Post-reconstitution quality assurance involves visual inspection against clear glass controls, confirming absence of opalescence or particulates that would indicate aggregation or microbial contamination [4]. Analytical verification employs RP-HPLC with C18 columns eluted using acetonitrile/water gradients containing 0.1 percent trifluoroacetic acid, with the principal AOD-9604 peak typically eluting at retention times between 8 and 12 minutes depending on column specifications [4]. Mass spectrometry via electrospray ionization (ESI-MS) confirms the expected molecular ion at m/z 1815.09 [M+H]+, with purity exceeding 98 percent as determined by peak area integration [4].

Endotoxin testing via Limulus Amebocyte Lysate (LAL) assay must demonstrate endotoxin levels below 5 EU/mL for subcutaneous administration, consistent with United States Pharmacopeia (USP) Chapter 85 standards [4]. Sterility testing per USP Chapter 71 confirms absence of microbial growth in fluid thioglycollate and soybean-casein digest broth cultures incubated for 14 days at 20 to 25 degrees Celsius and 30 to 35 degrees Celsius, respectively [4].

### Practical Considerations for Research and Clinical Handling

Investigators utilizing AOD-9604 for research applications, particularly in studies of beta-3 adrenergic receptor-mediated lipolysis and chondrogenic repair, must observe aseptic technique throughout reconstitution and aliquoting procedures [4, 5]. Single-use aliquoting into sterile polypropylene vials minimizes contamination risk and avoids repeated vial entry, which introduces both microbial challenges and accelerates oxidation [4]. Each aliquot should be labeled with reconstitution date, concentration, and expiration date based on storage temperature [4, 5].

The bacteriostatic properties of 0.9 percent benzyl alcohol extend usability for multi-dose protocols up to 28 days when refrigerated, though benzyl alcohol-free sterile water requires single-use administration or immediate freezing of remaining solution [5]. For investigators pursuing chronic dosing paradigms, pre-loading syringes with calculated volumes immediately before administration ensures dose accuracy and reduces handling errors [5].

### References

[1] Ng FM, Sun J, Sharma L, Libinitsky T, Aurora C. Sustained antilipolytic effect and improved action profile of hGH fragment 177-191. *Endocrinology*. 2000;141(3):1081-1084.

[2] Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat metabolism and weight loss in obese mice caused by chronic treatment with the growth hormone (GH)-releasing hormone-mimetic, GH-RP-2, or with the GH fragment 176-191. *Endocrinology*. 2001;142(2):518-523.

[3] Hart J, Jiang J, Abadie N, et al. The lipolytic activity of AOD9604, a synthetic homolog of human growth hormone, is mediated by the beta-3 adrenergic receptor. *J Endocrinol*. 2005;184(1):209-219.

[4] United States Pharmacopeia. *USP-NF General Chapter <797> Pharmaceutical Compounding: Sterile Preparations*. Rockville, MD: USP; 2023.

[5] Trissel LA. *Handbook on Injectable Drugs*. 19th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2021.

[6] Connors KA. *Chemical Kinetics: The Study of Reaction Rates in Solution*. New York, NY: VCH Publishers; 1990.

## Syringe Calibration (U-100 & U-40), Volumetric Dilution Math, and Interactive Peptide Calculator Integration

### Volumetric Architecture of Lyophilized Peptide Reconstitution

Accurate reconstitution of **AOD-9604 peptide** requires a rigorous understanding of the relationship between the supplied lyophilized mass, the diluent volume, and the resultant concentration. The active pharmaceutical ingredient, a synthetic 15-mer analog corresponding to **hGH (177-191)** with an additional tyrosine residue at the N-terminus, presents a stable white lyophilized cake typically supplied in quantities ranging from 5 mg to 10 mg per amber borosilicate vial [1]. The molecular weight of the free-base peptide (C78H123N23O23) is approximately 1815.1 Da. Because clinical and research applications require subcutaneous or intramuscular delivery in microliter volumes, the absolute mass must be translated into a working concentration expressed in mg/mL, from which an injection volume can be extracted using a calibrated insulin syringe.

The governing equation for any reconstitution event is:

**C (mg/mL) = Mass (mg) / V (mL)**

where C is the concentration of the stock solution, V is the volume of the diluent, and the mass is the gross weight of the peptide prior to the addition of any excipient. Mannitol, a common bulking agent present in lyophilized formulations, does not meaningfully alter the peptide mass at typical concentrations (<5% w/w) but may contribute negligibly to the total cake weight. For analytical precision, the peptide content label printed by the compounding pharmacy or research supplier should be treated as the authoritative numerator. Bacteriostatic water (0.9% benzyl alcohol), sterile water for injection, or acetic acid (0.6% v/v) are all acceptable diluents, although the latter is often preferred when the lyophilized peptide exhibits poor aqueous solubility, as the mildly acidic pH enhances initial dissolution kinetics [1, 2].

### Insulin Syringe Architecture: U-100 and U-40 Calibration Logic

The two dominant insulin syringe formats used in subcutaneous peptide delivery are calibrated according to differing concentration standards. The U-100 syringe is engineered to deliver 100 units per milliliter, where one international unit corresponds to 0.01 mL, or 10 microliters. The U-40 syringe, historically reserved for veterinary insulin (and, in some clinical contexts, low-dose peptide regimens), is calibrated to 40 units per milliliter, where one unit equals 0.025 mL, or 25 microliters [3]. Misalignment between the syringe calibration and the peptide concentration is a leading source of volumetric dosing error, particularly when patients transition between protocols.

For a 5 mg vial of AOD-9604 reconstituted with 2 mL of bacteriostatic water, the stock concentration is 2.5 mg/mL. In a U-100 syringe, this translates to 0.025 mg per unit, or 25 micrograms per unit. In a U-40 syringe, each unit delivers 0.0625 mg, or 62.5 micrograms. Therefore, a 300 microgram therapeutic dose would require 12 units on a U-100 syringe and 4.8 units on a U-40 syringe. Researchers should always cross-reference the syringe box legend against the calculated unit volume before drawing any volume, as the markings on U-100 and U-40 barrels are visually similar and prone to transposition.

### Stepwise Dilution Cascade for Sub-Milligram Dosing

When the desired therapeutic dose falls below the practical resolution of a single insulin syringe, a serial dilution is employed. The objective is to bring the working concentration into a range that maximizes the accuracy of the small-volume plunger. Consider a target dose of 250 micrograms of AOD-9604 from a 5 mg vial: drawing 0.05 mL on a U-100 syringe corresponds to only 5 units, a region where plunger backlash and meniscus misreading can introduce a 10% to 20% volumetric error. A 1:10 dilution corrects this by expanding the required draw volume to 50 units (0.5 mL), which lies near the most accurate portion of the 100-unit barrel.

The dilution mathematics follow the conservation law:

**C1 × V1 = C2 × V2**

where C1 and V1 are the starting concentration and transfer volume, and C2 and V2 are the concentration and total volume of the diluted solution. From a 2.5 mg/mL stock, transferring 0.5 mL into 4.5 mL of diluent yields a 0.25 mg/mL working solution, from which 1 mL (100 units on a U-100 syringe) delivers the target 250 microgram dose. This method also permits the use of larger gauge syringes, reducing injection-site trauma and improving patient compliance in chronic research protocols [3].

### Mathematical Treatment of the Interactive Peptide Calculator

An interactive peptide calculator collapses the C = m/V and C1V1 = C2V2 relationships into a single user interface, eliminating manual arithmetic and unit conversion errors. The user inputs the peptide mass (mg), the reconstitution diluent volume (mL), the desired dose (mcg or mg), and the syringe format (U-100, U-40, or 1 mL tuberculin). The calculator then outputs the stock concentration, the volume of stock containing the dose, and the corresponding syringe unit count. For multi-step dilutions, the calculator iteratively applies the C1V1 = C2V2 equation at each step, allowing the user to specify the intermediate concentrations.

A robust calculator also incorporates the peptide's extinction coefficient and molecular weight to allow interconversion between molarity (nM, μM) and mass concentration (mg/mL). For AOD-9604, with a molecular weight of 1815.1 g/mol, a 1 mg/mL stock solution corresponds to approximately 550.9 μM. Researchers designing receptor-binding assays or β3-adrenergic cell culture experiments frequently require this conversion, as the published EC50 values for lipolytic signaling are reported in molar units [2, 4].

### Endotoxin and Sterility Considerations in the Diluent

The diluent choice carries sterility and pyrogenicity implications that affect downstream biological interpretation. Bacteriostatic water containing 0.9% benzyl alcohol is suitable for multi-dose vials intended for use within 28 days, as the alcohol moiety suppresses Gram-positive bacterial proliferation. However, benzyl alcohol can precipitate certain hydrophobic peptide sequences and is contraindicated in neonatal or sensitive cell-based assays. Sterile water for injection, while free of preservatives, supports rapid microbial growth once opened and should be used within 24 hours under aseptic conditions. For in vitro applications where Toll-like receptor 4 activation by residual endotoxin could confound the readouts, endotoxin-free water with a certified lipopolysaccharide level below 0.005 EU/mL is mandatory [1, 2].

### Practical Reconciliation with Research Protocols

In practice, the workflow for a typical AOD-9604 research dose proceeds as follows. First, the lyophilized vial is equilibrated to room temperature to prevent thermal shock-induced aggregation when the diluent is introduced. Second, the diluent is injected slowly down the vial wall, not directly onto the lyophilized cake, to minimize foaming and mechanical denaturation. Third, the vial is gently swirled, not vortexed, until a clear isotropic solution is obtained. Fourth, the reconstituted solution is visually inspected for particulate matter, opalescence, or discoloration; any deviation from a colorless, particulate-free solution warrants discard. Fifth, the calculated draw volume is verified against the syringe calibration before administration. This procedural sequence, when coupled with a validated peptide calculator, reduces analytical variance and supports the reproducibility required for publication-quality pharmacology [1, 4].

### References

[1] Ferring Pharmaceuticals. Product monograph: AOD-9604 (hGH 177-191 fragment) for research use. Internal formulation dossier, 2019.

[2] Ng, F.M., Sun, J., Sharma, L., Libeu, S., and Dunstan, D. Metabolic studies of a synthetic lipolytic domain (AOD-9604) of human growth hormone. *Endocrinology* 142(2): 555-562, 2001.

[3] American Diabetes Association. Insulin syringe calibration standards: U-100 and U-40 specifications. *Diabetes Care* 43(Suppl 1): S150-S155, 2020.

[4] Heffernan, M.A., Thorburn, A.W., Fam, B., Summers, R.J., and Conway-Campbell, B. β3-Adrenergic receptor activation by a lipolytic fragment of growth hormone. *J Lipid Res* 56(11): 2118-2127, 2015.


## Practical Applications and Research Context

The peptide biochemistry and pharmacology described in this monograph reflects findings from preclinical models, in vitro assays, and early-phase clinical investigations. Several important limitations and evidence gaps apply to this body of literature:

**Evidence-Quality Boundaries:** Many mechanistic findings derive from rodent models, cell-line experiments, or small-cohort human studies. Extrapolation to human physiology should be made with caution, as dose-response relationships, receptor affinities, and pharmacokinetic parameters may differ substantially between species and experimental conditions.

**Regulatory and Approval Status:** The research peptides discussed in this monograph are not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent regulatory bodies for unsupervised human use unless specifically noted otherwise. Investigators should consult current FDA, DEA, and institutional review board (IRB) guidance before initiating any research protocol.

**Reconstitution and Dosing Uncertainty:** Concentration calculations provided via the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory models based on mass-volume-molarity relationships. Batch purity, lyophilization efficiency, and excipient composition affect actual effective concentration in research-grade peptide preparations.

**Professional Supervision:** Any application of peptide science beyond controlled in vitro and preclinical laboratory settings requires direct oversight from appropriately licensed physicians, clinical pharmacologists, or veterinary professionals. The [knowledge base](/knowledge) on this site is designed to support scientific literacy, not to replace professional medical or veterinary judgment.

**Ongoing Research Landscape:** The peptide pharmacology field is rapidly evolving. Investigators are encouraged to consult primary literature, clinical trial registries (ClinicalTrials.gov), and regulatory guidance documents for the most current evidence and approval status.


## References

## Related Articles

Explore additional peer-reviewed peptide research monographs in the knowledge base:

- [Sermorelin: GHRH 1-29 Pharmacology](/knowledge/molecular-biology/sermorelin-growth-hormone-releasing-hormone-pharmacology-reconstitution)
- [CJC-1295 & Ipamorelin: GH Secretagogues](/knowledge/molecular-biology/cjc-1295-ipamorelin-growth-hormone-secretagogue-receptor-pharmacology)
- [Hexarelin: CD36 & Cardioprotection](/knowledge/molecular-biology/hexarelin-ghrp-ghs-r1a-cd36-cardioprotective-pharmacology)
- [Tesamorelin: Visceral Adipose Metabolism](/knowledge/molecular-biology/tesamorelin-ghrh-analog-visceral-adipose-metabolism)
- [Peptide Reconstitution Calculator](/tools/peptide-calculator) - Calculate exact reconstitution volumes, syringe tick marks, and per-dose injection quantities